

# Community Acquired Pneumonia (CAP) R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/CB881313CDC3EN.html>

Date: October 2020

Pages: 101

Price: US\$ 1,699.00 (Single User License)

ID: CB881313CDC3EN

## Abstracts

### Community Acquired Pneumonia (CAP) Pipeline Overview

The Q4 Community Acquired Pneumonia (CAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Community Acquired Pneumonia (CAP), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

### Community Acquired Pneumonia (CAP) Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Community Acquired Pneumonia (CAP) disease overview, Community Acquired Pneumonia (CAP) types, Community Acquired Pneumonia (CAP) symptoms, causes, and FDA/EMA approved treatment options.

### Community Acquired Pneumonia (CAP) Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Community Acquired Pneumonia (CAP) indication. The report presents near-term and long-term pipeline development trends and potential insights.

### Community Acquired Pneumonia (CAP) Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 17 companies. Business profiles and contact details of the companies actively perusing Community Acquired Pneumonia (CAP) pipeline are assessed.

## Community Acquired Pneumonia (CAP) R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Community Acquired Pneumonia (CAP) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Community Acquired Pneumonia (CAP) companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Community Acquired Pneumonia (CAP) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

## Community Acquired Pneumonia (CAP) Pipeline Market News and Developments during 2020

The Community Acquired Pneumonia (CAP) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

## Community Acquired Pneumonia (CAP) Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

## New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

## Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

## Scope and Coverage

Community Acquired Pneumonia (CAP) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic

candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

17 companies are included including Basilea Pharmaceutica Ltd , BioAegis Therapeutics Inc, Biotest AG , Combioxin SA, InflaRx NV, ioGenetics, LLC, Iterum Therapeutics Plc , KYORIN Pharmaceutical Co.,Ltd, La Jolla Pharmaceutical Company, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Nabriva Therapeutics Plc, Paratek Pharmaceuticals, Inc., ProThera Biologics LLC, TaiGen Biotechnology Co., Ltd., TiGenix NV, Wockhardt Ltd,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Community Acquired Pneumonia (CAP) pipeline market

## Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

## Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Community Acquired Pneumonia (CAP) Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Community Acquired Pneumonia (CAP) Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Community Acquired Pneumonia (CAP) pipeline
- 2.5 Active Companies Developing Community Acquired Pneumonia (CAP) pipeline

### 3. COMMUNITY ACQUIRED PNEUMONIA (CAP) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

### 4. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 Basilea Pharmaceutica Ltd
- BioAegis Therapeutics Inc
- Biotest AG
- Combioxin SA
- InflaRx NV
- ioGenetics  
LLC
- Iterum Therapeutics Plc
- KYORIN Pharmaceutical Co.
- Ltd

La Jolla Pharmaceutical Company  
Meiji Seika Pharma Co Ltd  
Merck & Co Inc  
Nabriva Therapeutics Plc  
Paratek Pharmaceuticals  
Inc.  
ProThera Biologics LLC  
TaiGen Biotechnology Co.  
Ltd.  
TiGenix NV  
Wockhardt Ltd

## **5. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE DRUG PROFILES**

### 5.1 Current Status of Drug and Vaccine Candidates

#### 5.2 Drug Snapshot

##### 5.2.1 Drug

##### 5.2.2 Mechanism of Action

##### 5.2.3 Phase

##### 5.2.4 Co-Developer

##### 5.2.5 Originator

##### 5.2.6 Synonym

##### 5.2.7 Route of Administration

##### 5.2.8 Type of Molecule

##### 5.2.9 Orphan Drug Status

##### 5.2.10 New Molecular Entity

##### 5.2.11 Area

#### 5.3 Drug Details

#### 5.4 Mechanism of Action

#### 5.5 Licensing/Collaboration Agreements

#### 5.6 Clinical Trial Details

## **6. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020**

## **7. APPENDIX**

### 7.1 About the Publisher

### 7.2 Sources and Research Methodology

## I would like to order

Product name: Community Acquired Pneumonia (CAP) R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/CB881313CDC3EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB881313CDC3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970